R-mabHDI and ABVD + ABVD
Phase 3UNKNOWN 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Hodgkin's Lymphoma
Conditions
Hodgkin's Lymphoma
Trial Timeline
Jul 1, 2011 โ Apr 1, 2014
NCT ID
NCT00816959About R-mabHDI and ABVD + ABVD
R-mabHDI and ABVD + ABVD is a phase 3 stage product being developed by Eli Lilly for Hodgkin's Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00816959. Target conditions include Hodgkin's Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00816959 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Hodgkin's Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Nivolumab + Brentuximab vedotin | Ono Pharmaceutical | Phase 3 | 77 |
| Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine | Eli Lilly | Phase 1/2 | 41 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| R-mabHD + ABVD | Eli Lilly | Phase 2 | 52 |
| LY317615 | Eli Lilly | Phase 2 | 52 |
| LY4584180 + Rituximab | Eli Lilly | Phase 1 | 33 |
| Bortezomib + Rituximab + Rituximab | Johnson & Johnson | Phase 3 | 77 |
| HRS-3738 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR1459 ๏ผYY-20394 + SHR1459 ๏ผYY-20394 + Gemcitabine-Oxaliplatin | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-199 + Ketoconazole | AbbVie | Phase 1 | 33 |
| ABT-199 + Rifampin | AbbVie | Phase 1 | 33 |
| [14C]ABT-199 (GDC-0199) | AbbVie | Phase 1 | 33 |
| ABT-199 + Rituximab + Bendamustine | AbbVie | Phase 1 | 33 |